New blood test could replace risky amniocentesis for down syndrome detection
NCT ID NCT01725438
First seen Apr 22, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study tested a new, non-invasive blood test to diagnose Down syndrome (trisomy 21) during pregnancy. Current screening methods have high false-positive rates, and the only way to confirm a diagnosis is through invasive procedures like amniocentesis, which carry a 1-3% risk of miscarriage. The new method analyzes fetal cells from a mother's blood sample, aiming to provide a safe and accurate alternative. The study involved 150 pregnant women at high risk for trisomy 21.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRISOMY 21 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital de Béclère
Clamart, 75014, France
Conditions
Explore the condition pages connected to this study.